ALX Oncology (ALXO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
16 Nov, 2026Executive summary
Clinical-stage pipeline centers on evorpacept and ALX2004; no product revenue has been generated, and net losses are expected to continue.
Q3 GAAP net loss was $21.8M; 9M net loss was $57.7M, down from $78.8M in 9M 2025.
Cash, cash equivalents and investments totaled $147.2M at Sept. 30, 2026, supporting a projected operating runway through H1 2028.
Financial highlights
Q3 operating expenses were $22.9M vs. $22.5M YoY; 9M expenses were $59.9M vs. $81.0M.
Q3 R&D was $17.5M vs. $17.4M YoY; 9M R&D declined 26% to $44.2M, primarily due to fewer active trials, pipeline prioritization and reduced workforce costs.
Q3 G&A rose 8% to $5.5M from $5.1M; 9M G&A fell 14% to $16.0M.
Q3 loss per basic and diluted share was $0.15 vs. $0.41; 9M loss per share was $0.45 vs. $1.48.
Q3 non-GAAP net loss was $18.9M vs. $19.6M; 9M non-GAAP net loss was $48.6M vs. $65.6M.
Outlook and guidance
Existing cash, cash equivalents and investments are expected to fund planned operations through H1 2028; actual cash use could exceed estimates.
Topline ASPEN-09-Breast data from 120 patients are expected in 2H 2027.
ALX2004 Phase 1 safety and early efficacy results from 35 enrolled patients are expected in December 2026.
Significant expenses and increasing operating losses are expected as evorpacept and ALX2004 advance through clinical development, manufacturing and pre-commercial work; additional capital will be needed to fully implement the business plan.
Latest events from ALX Oncology
- Biomarker-led evorpacept and ALX2004 anchor catalysts through 2027.ALXO
Corporate presentation - Lead assets advance toward phase III, with strong biomarker focus and robust financial runway.ALXO
H.C. Wainwright 28th Annual Global Investment Conference - Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers.ALXO
12th Annual Cantor Fitzgerald Global Healthcare Conference - ALX2004 and evorpacept advance toward registrational trials, targeting key oncology indications.ALXO
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028.ALXO
Q2 2026 - First randomized CD47 solid tumor trial shows strong efficacy, fueling expansion and partnership talks.ALXO
2024 Cantor Fitzgerald Global Healthcare Conference - Two high-value oncology programs advance toward pivotal data with strong financial support.ALXO
Jefferies London Healthcare Conference 2025 - Evorpacept plus PADCEV achieved a 59–62% response rate with favorable safety in advanced bladder cancer.ALXO
Study Update - Evorpacept advances in pivotal trials, extends cash runway, and prepares new ADC for the clinic.ALXO
Status Update